Danaher Corporation (DHR)
| Market Cap | 186.74B |
| Revenue (ttm) | 30.28B |
| Net Income (ttm) | 6.29B |
| Shares Out | 727.08M |
| EPS (ttm) | 8.64 |
| PE Ratio | 29.73 |
| Forward PE | 23.70 |
| Dividend | $0.92 (0.36%) |
| Ex-Dividend Date | Jun 23, 2022 |
| Volume | 2,780,826 |
| Open | 255.61 |
| Previous Close | 255.18 |
| Day's Range | 253.73 - 257.34 |
| 52-Week Range | 233.71 - 333.96 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 334.98 (+30.4%) |
| Earnings Date | Jul 21, 2022 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filt... [Read more...]
Financial Performance
In 2021, Danaher's revenue was $29.45 billion, an increase of 32.17% compared to the previous year's $22.28 billion. Earnings were $6.43 billion, an increase of 76.44%.
Financial StatementsAnalyst Forecast
According to 28 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is 334.98, which is an increase of 30.43% from the latest price.
News
Danaher (DHR) Exhibits Bright Prospects, Headwinds Persist
Danaher (DHR) gains from solid demand for its products, acquired assets and shareholder-friendly policies. However, escalating costs and high debt levels remain concerns.
Find businesses consumers have a harder time trading down, says FBB's Mike Bailey's
Mike Bailey, FBB Capital Partners director of research, joins 'Power Lunch' to discuss overcoming market fears and finding opportunities in a volatile market.
Danaher Schedules Second Quarter 2022 Earnings Conference Call
WASHINGTON , June 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2022 on Thursday, July 21, 2022 be...
MARUY or DHR: Which Is the Better Value Stock Right Now?
MARUY vs. DHR: Which Stock Is the Better Value Option?
5 High-Performing Stocks Ron Baron and Daniel Loeb Both Own
According to the All-in-One Screener, a Premium feature of GuruFocus, five stocks that Ron Baron (Trades, Portfolio) and Daniel Loeb (Trades, Portfolio) both agree on and have outperformed the Standard ...
Two-minute drill: ADBE, DHR & CCI
Ayako Yoshioka, Wealth Enhancement Group senior portfolio manager, joins 'Closing Bell: Overtime' to discuss some of her top names for investors' portfolios in the current environment.
SCIEX Launches the Next Generation of Data Independent Acquisition With Zeno SWATH DIA at ASMS 2022
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ASMS--SCIEX launches the next generation of Data Independent Acquisition with Zeno SWATH DIA at ASMS 2022.
SCIEX Launches the New Cornerstone of Software Ecosystem - SCIEX OS 3.0
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ASMS--SCIEX launches the new cornerstone of software ecosystem - SCIEX OS 3.0 - featuring Zeno SWATH DIA, stMRM and accessibility across 9 languages.
Top Wall Street analysts are gaining more confidence in these stocks
TipRanks analyst ranking service pinpoints Wall Street's picks for best-performing stocks, including Nvidia and Marvell.
Billionaire Dan Loeb Is Betting Big on These 3 Stocks
Dan Loeb is a veteran hedge fund manager and the CEO of Third Point. Let's take a look at his top three positions as of Q1.
MS Global Franchise Portfolio's Top 5 1st-Quarter Buys
The MS Global Franchise Portfolio (Trades, Portfolio), part of Morgan Stanley's ( MS , Financial) mutual funds, disclosed in a regulatory filing that its top five buys during the first quarter included ...
MARUY vs. DHR: Which Stock Is the Better Value Option?
MARUY vs. DHR: Which Stock Is the Better Value Option?
Danaher Joins Bespoke Gene Therapy Consortium (BGTC) for Rare Diseases
Consortium aims to speed the development and delivery of customized or 'bespoke' gene therapies WASHINGTON , May 12, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it has joined the...
The fundamentals are in good shape for Danaher, says FBB Capital Partners' Mike Bailey
Mike Bailey, FBB Capital Partners director of research, joins 'Power Lunch' to discuss the FAANG 'survivors,' companies that are compelling at these lower levels and more.
DANAHER ANNOUNCES QUARTERLY DIVIDENDS
WASHINGTON , May 10, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.25 per share of its common stoc...
RNA 9000 Purity and Integrity Kit Allows for Critical High-Resolution Analysis for mRNA Therapeutics
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #EL--At TIDES 2022, SCIEX, a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches the RNA 9000 Purity & I...
Down 25% in 2022: Buy This High-Quality Stock on a Dip?
Danaher's long-term prospects are being ignored because of the near-term speculation around how long the pandemic will last.
Danaher To Present At Bank Of America Securities Health Care Conference
WASHINGTON , May 4, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Healt...
Buy 'gift horse' Danaher while it's down but leave room for other stocks, Cramer says
The "Mad Money" host explained why investors should act fast to purchase Danaher stock on Friday's episode of the show.
Will Danaher reverse the trend of the declining share price after Q1 results?
Danaher Corporation (NYSE:DHR) had several weeks of downward pressure on the price. The stock appears to have consolidated in the range between $262 and $297.
All You Need to Know About Danaher (DHR) Rating Upgrade to Buy
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Danaher gets lift from Covid testing, but core business is also humming
We expect some noise around Covid testing quarter to continue as we work through China lockdowns, we think it's a distraction from Danaher's long-term story.
Danaher's (DHR) Q1 Earnings & Revenues Beat, Increase Y/Y
Danaher's (DHR) first-quarter 2022 revenues increase 12% year over year driven by impressive performance across its segments.